← Eichor
Study identifier: NCT06055517 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Use of Pulsed Low-dose Rate Re-irradiation for Recurrent Glioma (PULSAR)

Condition: Glioma  ·  Sponsor: Centro di Riferimento Oncologico - Aviano

PhaseNA
Planned participants29
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

Re-irradiation in gliomas is a therapeutic option at recurrence before of 2nd-line chemotherapy. The dose of re-irradiation with conventional fractionation is unfortunately limited by the risk of symptomatic radionecrosis that is significant for cumulative doses above 100 Gy. The use of unconventional low dose rate pulsed radiotherapy (pLDRT) can reduce the risk of radiotoxicity while taking advantage of the cellular hyper-radiosensitivity that occurs at low dose-rates. The present study therefore aims at evaluating whether the use of pLDRT in the re-irradiation of recurrences of gliomas allows maintaining a low risk of symptomatic radionecrosis even for cumulative doses greater than 100 Gy.

This description comes directly from the study's public registry record.

Talk to the study team

Lorenzo Vinante, MD  ·  0434659855  ·  lorenzo.vinante@cro.it

Always discuss trial participation with your own doctor first.

Locations (1)

IRCCS-Centro di Riferimento Oncologico (CRO) di AvianoAviano, Pordenone, ItalyRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06055517